Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.
A new report from IMARC Group expects Amgen to lose brand sales worth US$ 8.4 Billion during 2010 and 2020 mainly as a result of biosimilar erosion.
Page 1 of 1